Both in Biotechnology
Exelixis vs Repligen
Over the past year EXEL returned +79.4% and RGEN returned +18.7%; their daily moves had a correlation of 0.23.
EXEL +79.4% RGEN +18.7%Growth of $1, one year, split-adjusted
| Metric | EXEL | RGEN |
|---|---|---|
| Price | $69.39 | $176.94 |
| Market cap | $16.93B | $11.23B |
| Today | +4.82% | −6.20% |
| 1 month | +19.8% | −0.2% |
| 6 months | +58.9% | +51.0% |
| Year to date | +58.3% | +8.0% |
| 1 year | +76.0% | +19.2% |
| Revenue growth (YoY) | +10.2% | +10.9% |
| Gross margin | 96.0% | 53.0% |
| Net margin | 33.1% | −18.4% |
| P/E (TTM) | 19.1× | — |
| Price / sales | 6.8× | 13.9× |
| Net cash | $892.0M | $307.4M |
| Dividend yield | — | — |
| Volatility (60d) | 27.5% | 47.0% |
| Short % of float | 11.4% | 12.8% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).